High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies

References

• Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652. doi:10.1056/NEJMoa1000067
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607. doi:10.1056/NEJMoa1408648
   PubMed Web of Science ®Google Scholar
• André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794. doi:10.1200/JCO.2016.68.6394
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212. doi:10.1056/NEJMoa1100340
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi:10.1056/NEJMoa1510093
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Gioia DM, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34(12):1376–1385. doi:10.1200/JCO.2015.63.0699
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan After two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462. doi:10.1200/JCO.2017.75.2543
   PubMed Web of Science ®Google Scholar
• Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach for stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246. doi:10.1182/blood.2019000719
   PubMed Web of Science ®Google Scholar
• Linch P, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. doi:10.1016/0140-6736(93)92411-l
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the grupo español de linfomas/transplante autólogo de médula osea spanish cooperative group. J Clin Oncol. 2001;19(5):1395–1404. doi:10.1200/JCO.2001.19.5.1395
   PubMed Web of Science ®Google Scholar
• Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer. 2003;97(11):2748–2759. doi:10.1002/cncr.11414
   PubMed Web of Science ®Google Scholar
• Viviani S, Di Nicola M, Bonfante V, et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma. 2010;51(7):1251–1259. doi:10.3109/10428194.2010.486090
   PubMed Web of Science ®Google Scholar
• Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2014;92(1):1–10. doi:10.1016/j.critrevonc.2014.04.003
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–3058. doi:10.1200/JCO.2013.53.5229
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. NCCN guidelines® insights: Hodgkin lymphoma, version 2.2022. J Natl Compr Canc Netw. 2022;20(4):322–334. doi:10.6004/jnccn.2022.0021
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790–2802. doi:10.1016/S0140-6736(17)32134-7
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566. doi:10.1182/blood-2016-02-699850
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. doi:10.1200/JCO.2017.76.0793
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153. doi:10.1182/blood.2019000324
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Nieto Y, Gruschkus S, Valdez BC, et al. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022;107(4):899–908. doi:10.3324/haematol.2021.278311
   PubMed Web of Science ®Google Scholar
• Shah H, Jang H, Singh P, et al. Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma. 2022;63(4):813–820. doi:10.1080/10428194.2021.2002322
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625–633. doi:10.1093/annonc/mdi119
   PubMed Web of Science ®Google Scholar
• Shah GL, Yahalom J, Matasar MJ, et al. Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Br J Haematol. 2016; Nov175(3):440–447. doi:10.1111/bjh.14245
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–1670. doi:10.1182/blood-2011-10-388058
   PubMed Web of Science ®Google Scholar
• Damlaj M, Ghazi S, Syed G, et al. Pre-autologous transplantation PET/CT using deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2017;52(9):1342–1344. doi:10.1038/bmt.2017.143
   PubMed Web of Science ®Google Scholar
• LaCasce A, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48. Jul 5 doi:10.1182/blood-2017-11-815183
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five‐year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi:10.1182/blood-2018-07-861641
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. Pembroli­zumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–524. doi:10.1016/S1470-2045(21)00005-X
   PubMedGoogle Scholar
• Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142Jun 15: blood.(10):878–886. doi:10.1182/blood.2022019386
   PubMed Web of Science ®Google Scholar